Qiming Venture Partners' Alex Zhou: AXERA's "Chip and AI" Expertise and Platform Strategy Built Its Success
Qiming Venture Partners has landed its third AI-related IPO in less than 40 days since the start of 2026.
@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
Qiming Venture Partners has landed its third AI-related IPO in less than 40 days since the start of 2026.
Qiming Venture Partners led Aixin Yuanzhi's Pre-A funding round in early 2020, becoming the company's earliest investor, and continued to support the company's growth in two subsequent funding rounds.
Recognizing investment institutions and individuals who have demonstrated sustained commitment and achieved outstanding results in the equity investment industry over the past year.
From Qiming Venture Partners' perspective, an increasing number of Chinese medical innovations are demonstrating internationally leading clinical value, and their global competitiveness is rapidly rising.
In 2020, Qiming Venture Partners led the Series C round for NorthSea Therapeutics and continued to support the company's growth in its Series D round.
Recognizing outstanding organizations and individuals who have forged ahead with remarkable achievements over the past year, setting new benchmarks for industry development.
Celebrating milestone moments with you at Qiming Venture Partners' portfolio companies
From one angle, this reflects China's influence in the global private equity market.
Thirteen years, over 100 portfolio companies, covering the full AI industry chain.
This is intended to encourage outstanding institutions and talent in private equity fund-of-funds and the broader fund industry, and to promote the healthy development of equity investment.